Trial Profile
Phase 1b/2a Study of OPT-302 in Combination With Aflibercept for Persistent Central-involved Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jun 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Sozinibercept (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Opthea
- 26 Nov 2020 Status changed from active, no longer recruiting to completed.
- 17 Sep 2020 This trial has been completed in Latvia, according to European Clinical Trials Database record.
- 27 Jul 2020 Results presented in an Opthea media release.